ClinicalTrials.gg
CompletedNCT06362668FASTR-EUUpdated Mar 10, 2025

EU Sites: Fluid Management of Acute Decompensated Heart Failure With Reprieve Decongestion Management System (FASTR-EU)

An interventional study of Reprieve Decongestion Management System and Diuretic (furosemide, bumetanide, torsemide, hydrochlorothiazide, and/or acetazolamide) in Acute Decompensated Heart Failure, sponsored by Reprieve Cardiovascular, Inc. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-10.

Sponsored by Reprieve Cardiovascular, Inc · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Oct 2024, 2 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 313 studies in Heart Failure with a site in Netherlands — 57 open to participants now, 80 under way, 13 of them phase 3. Heart Failure · Netherlands.

Enrollment
222nd of 234
12 · median 284
Started
2024
with 19 others
No phase
105 of 313
19 open now
Registered
267th of 313
by date

Among the 313 studies in Heart Failure with a site in Netherlands, this one is the 222nd largest by enrollment of the 234 interventional ones that give a count, is one of 20 that started in 2024, is one of 105 with no phase, and was the 267th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

57 of the 313 studies in Heart Failure with a site in Netherlands are open now. Recruiting first, the newest first:

52 more — sign in →

All 57 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 313 studies in Heart Failure with a site in Netherlands, or all of them as a file.
02

Study summary

The objective of this study is to prospectively compare decongestive therapy administered by the Reprieve DMS system to Optimal Diuretic Therapy (ODT) in the treatment of patients diagnosed with acute decompensated heart failure (ADHF). The main objective is to determine if the Reprieve DMS is non-inferior to state-of-the-art urine sodium guided aggressive diuretic titration in two European HF centers of excellence.

03

Conditions studied

  • Acute Decompensated Heart Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Hospitalized with a diagnosis of heart failure as defined by the presence of at least 1 symptom AND 1 sign.
  2. ≥10 pounds (4.5 kg) above dry weight either by historical weights or as estimated by health care provider.
  3. Prior use of loop diuretics within 30 says prior to admission.
  4. ≥ 18 years of age able to provide and comply with study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Inability to place Foley catheter or IV catheter.
  2. Hemodynamic instability.
  3. Dyspnea due primarily to non-cardiac causes.
  4. Acute infection with evidence of systemic involvement.
  5. Estimated (eGFR) \< 20 ml/min/1.73m2 calculated using the MDRD equation or current use of renal replacement therapy.
  6. Significant left ventricular outflow obstruction, uncorrected complex congenital heart disease, severe stenotic valvular disease, infiltrative or constrictive cardiomyopathy, acute myocarditis, type 1 acute myocardial infarction requiring treatment, or any other pathology that, in the opinion of the investigator, would make aggressive diuresis poorly tolerated.
  7. Inability to follow instructions or comply with follow-up procedures.
  8. Other concomitant disease or condition that investigator deems unsuitable for the study, including drug or alcohol abuse or psychiatric, behavioral or cognitive disorders, sufficient to interfere with the patient's ability to understand and comply with the study instructions or follow-up procedures.
  9. Severe electrolyte abnormalities.
  10. Presence of active coronavirus disease 2019 (COVID-19) infection.
  11. Enrollment in another interventional trial during the index hospitalization.
  12. Inability to return for follow-up study visits.
  13. less than 3 months.
  14. Women who are pregnant or intend to become pregnant.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Reprieve Decongestion Management System

    Subjects randomized to Reprieve System will receive personalized and optimized diuretic and saline infusion using the study device during the course of the treatment.

    Device: Reprieve Decongestion Management System

  • Active comparator
    Optimal Diuretic Therapy

    Sites will consider best practices of optimal diuretic dosing such as those demonstrated in recent randomized trials \[Diuretic Strategies in Patients with Acute Heart Failure Trail (DOSE), Acetazolamide in Decompensated Heart Failure with Volume Overload Trial (ADVOR), and Safety and Efficacy of the Combination of Loop with Thiazide-type Diuretics in Patients with Decompensated Heart Failure Trial (CLOROTIC)\] for patients randomized to control arm of the trial.

    Drug: Diuretic (furosemide, bumetanide, torsemide, hydrochlorothiazide, and/or acetazolamide)

Interventions

  • DeviceReprieve Decongestion Management System

    The Reprieve Decongestion Management System, or Reprieve DMS, is a hospital bedside fluid management console designed to provide personalized and automated infusion of the IV diuretic furosemide and physiological saline in response to the patient's real-time urine output to safely and rapidly decongest patients suffering from Acute Decompensated Heart Failure.

  • DrugDiuretic (furosemide, bumetanide, torsemide, hydrochlorothiazide, and/or acetazolamide)

    Drug page: DiureticsStudies of DiureticsDiuretics pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Best practices of optimal diuretic dosing such as those demonstrated in recent randomized trials (DOSE, ADVOR, CLOROTIC).

06

What researchers measure

Primary outcomes

  1. Total sodium loss (in mmol of sodium) per 24 hours

    Primary efficacy endpoint is total sodium loss in mmol of sodium at end of randomized therapy normalized to 24 hours (up to a maximum of 72 hours).

    Time frame: End of treatment, an average of 72 hours

  2. Comparison of occurrence of composite endpoint comprised of clinically significant acute kidney injury, severe electrolyte abnormality, or symptomatic hypotension or hypertensive emergency.

    Primary safety endpoint is positive if any of the following occurs in an individual participant: 1. Clinically significant acute kidney injury defined as Kidney Disease-Improving Global Outcomes (KDIGO) stage 2 or greater Acute Kidney Injury (AKI) \[≥ doubling of baseline serum creatinine or use of renal replacement therapy (RRT)\] 2. Severe electrolyte abnormality defined as serum potassium \<3.0 milliequivalent/liter (mEq/L), magnesium \<1.3 mEq/L, or sodium \<135 mEq 3. Symptomatic hypotension (systolic pressure \<80mmHg) or hypertensive (systolic pressure \>200 mmHg and/or diastolic pressure \>120 mmHg) emergency.

    Time frame: Through study completion, an average of 90 days

Secondary outcomes

  1. Total net fluid volume loss (difference between urine output volume and fluid input volume) per 24 hours

    Difference between volume of urine output and fluid input during primary treatment normalized to 24 hours.

    Time frame: End of treatment, an average of 72 hours

  2. Weight loss per 24 hours at end of randomized therapy

    Total time on loop diuretics during primary treatment

    Time frame: End of treatment, an average of 72 hours

  3. Time on IV loop diuretic

    Total time on loop diuretics from initiation of randomized therapy to last dose of IV loop diuretic administered for ADHF

    Time frame: End of treatment, an average of 72 hours

  4. Number of participants with ≥ 0.3 mg/dL increase in serum creatinine

    In hospital worsening renal function defined as ≥ 0.3 mg/dL increase in serum creatinine during randomized therapy.

    Time frame: End of treatment, an average of 72 hours

07

Study locations

2 sites
  • University Medical Center Groningen
    Groningen, Netherlands
  • Wroclaw Medical University
    Wrocław, Poland
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2024 to primary completion in Oct 2024, 4 months.

Of 236 industry-sponsored interventional studies with no phase under Heart Failure, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 61. This study's 4 months is below that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2024
First posted
Apr 12, 2024
StartActual
May 17, 2024
Primary completionActual
Oct 1, 2024
CompletionActual
Oct 31, 2024
Last update
Mar 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06362668
Lead sponsor
Reprieve Cardiovascular, Inc
Responsible party
Sponsor
First posted
Apr 12, 2024
Start date
May 17, 2024
Primary completion
Oct 1, 2024
Completion
Oct 31, 2024
Last update
Mar 10, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion